Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kaposi's sarcoma: a reevaluation

C E Orfanos1, R Husak, U Wölfer

  • 1Department of Dermatology, University Medical Center Steglitz, Free University of Berlin, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pioneers in Dermatology and Venereology: an interview with Prof. Constantin Orfanos.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

[Not Available].

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2016
Same author

From Hippocrates to modern medicine.

Journal of the European Academy of Dermatology and Venereology : JEADV·2007
Same author

Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.

Journal of cutaneous pathology·2007
Same author

HIV - associated and non - HIV associated types of Kaposi's sarcoma in an African population in Tanzania. Status of immune suppression and HHV-8 seroprevalence.

European journal of dermatology : EJD·2007
Same author

Antigen mimicry, epitope spreading and the pathogenesis of pemphigus.

Tissue antigens·2006

Kaposi's sarcoma (KS) in HIV-infected individuals is a serious cancer. Prognosis is worse with lower CD4 counts and widespread disease, but some treatments like interferon alpha show therapeutic benefit.

Area of Science:

  • Oncology
  • Immunology
  • Infectious Diseases

Background:

  • Kaposi's sarcoma (KS) is a neoplasm of microvascular origin associated with human immunodeficiency virus (HIV) infection and immunodeficiency.
  • This study analyzes over 130 patients diagnosed with HIV-associated KS between 1982-1992, focusing on clinical presentation, prognostic factors, and outcomes.

Purpose of the Study:

  • To evaluate the clinical characteristics, prognostic predictors, and survival rates of patients with HIV-associated Kaposi's sarcoma.
  • To assess the impact of immunosuppression and disease manifestation on patient outcomes.
  • To review the efficacy of therapeutic interventions for HIV-associated KS.

Main Methods:

  • Retrospective analysis of 130+ HIV-associated KS patients diagnosed between 1982-1992.

Related Experiment Videos

  • Assessment of mucocutaneous and visceral involvement, CD4+ T-cell counts, and history of opportunistic infections.
  • Evaluation of survival data and response to treatments including interferon alpha, zidovudine, and chemotherapy.

    • Main Results:

    • Mucocutaneous and visceral involvement increased from 39% to 65% during follow-up.
    • Significant immunosuppression (CD4+ < 200/mm3) was present in 90% of patients at diagnosis.
    • Median survival was 17 months, significantly shorter for immunosuppressed patients (14 months) compared to those with >300 CD4+ cells (28 months). Disseminated KS was a major cause of death in 49% of deceased patients.
    • Recombinant interferon alpha (rIFN-alpha) combined with antiretroviral therapy showed therapeutic benefit in 30%-40% of patients, prolonging survival.

    Conclusions:

    • HIV-associated KS is a high-malignancy potential tumor with poor prognosis, strongly influenced by the degree of immunosuppression and disease dissemination.
    • Early diagnosis and treatment, potentially involving interferon alpha and antiretroviral therapy, may improve survival outcomes.
    • The exact etiology remains unknown, but co-infections and cytokines are suspected cofactors.